Triple
T5981396
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | ENGAGE (Study 301) |
E133124
|
entity |
| Predicate | sponsorProgram |
P24549
|
FINISHED |
| Object | aducanumab Phase 3 program |
E24938
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: aducanumab Phase 3 program | Statement: [ENGAGE (Study 301), sponsorProgram, aducanumab Phase 3 program]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: aducanumab Phase 3 program Context triple: [ENGAGE (Study 301), sponsorProgram, aducanumab Phase 3 program]
-
A.
Aduhelm
chosen
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Alzheimer’s Disease Research Centers program
The Alzheimer’s Disease Research Centers program is a nationwide network of specialized centers that conduct research, clinical care, and education focused on Alzheimer’s disease and related dementias.
-
D.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: sponsorProgram Context triple: [ENGAGE (Study 301), sponsorProgram, aducanumab Phase 3 program]
-
A.
sponsoredPrograms
chosen
Indicates that an entity provides financial or resource support to specific programs or initiatives.
-
B.
agencyProgramme
Indicates that an agency is responsible for, manages, or is associated with a particular programme.
-
C.
agencyProgramName
Indicates the specific program or initiative name associated with or administered by an agency.
-
D.
sponsorInHouse
Indicates that one entity formally supports, promotes, or funds another entity within the same organization, institution, or internal setting.
-
E.
sponsorType
Indicates the specific role or category of sponsorship that an entity provides in relation to another entity or event.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0086f45e8819098f73dd16d45ec9d |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04a6921b081908a6f6323d5c7a062 |
completed | March 22, 2026, 8 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c0e42174a88190b8b40cbc7815911f |
completed | March 23, 2026, 6:56 a.m. |
| PD | Predicate disambiguation | batch_69c049de98648190962b14fd341c93da |
completed | March 22, 2026, 7:58 p.m. |
Created at: March 22, 2026, 4:04 p.m.